5-HT TRANSPORTER IN PARKINSONS DISEASE--A PET STUDY

描述（改编自申请人的摘要）：5-HT的损失 （5-羟色胺，血清素）神经元在帕金森病已经 通过直接和间接测量建立。 直接测量 是在死后的材料上进行的， 免疫化学和放射自显影，无法应用的测量 在活着的病人身上。 间接证据是通过降低浓度 脑脊液中5-HT及其代谢产物的含量。 这些测量 是在活着的病人身上进行的，但它们不能提供直接的， 不同组织中5-HT神经元和轴突终末的定量估计 大脑的各个区域。 初步数据表明， 用PET和碳-11 McN 5652对人脑中的5-HT转运蛋白进行成像 并且在帕金森病患者中可以检测到5-HT转运蛋白的丢失 使用这种方法的疾病。 该项目的目的是定量地 测量5-HT转运蛋白的丢失和获得，并了解其临床 帕金森病的重要性。 以下具体假设将 1）放射性配体与5-HT转运蛋白的结合是 帕金森病的严重程度：2）临床 帕金森病的临床表现与定量数据相关 来自PET测量。 该项目的长期目标是 进一步阐明5-HT神经元丢失在帕金森病中的作用。 这将使我们更好地理解血清素的作用 增强药物治疗PD患者的效果。

DESCRIPTION (Adapted from Applicant's Abstract): Loss of 5-HT (5-hydroxytryptamine, serotonin) neurons in Parkinson's disease has been established with both direct and indirect measurements. Direct measurements are performed on postmortem material and include techniques of immunochemistry and autoradiography, measurements which can not be applied in living patients. Indirect evidence is provided by reduced concentrations of 5-HT and its metabolites in the cerebrospinal fluid. These measurements are performed in living patients, but they do not provide a direct, quantitative estimate of 5-HT neurons and axon terminals in different regions of the brain. Preliminary data indicate that it is feasible to image the 5-HT transporter in the human brain with PET and carbon-11 McN5652 and that 5-HT transporter loss can be detected in patients with Parkinson's disease using this method. The purpose of this project is to quantitatively measure 5-HT transporter loss and gain and understanding of its clinical significance in Parkinson's disease. The following specific hypotheses will be addressed: 1) Radioligand binding to the 5-HT transporter is significantly reduced in Parkinson's disease: 2) Severity of clinical manifestations of Parkinson's disease correlates with the quantitative data derived from PET measurements. The long term goal of this project is to further elucidate the role of 5-HT neuronal loss in Parkinson's disease. This should lead to a better understanding of the role of serotonin enhancing drugs in treating patients with PD.